StockNews.com lowered shares of ChromaDex (NASDAQ:CDXC - Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Thursday.
Several other brokerages have also recently issued reports on CDXC. LADENBURG THALM/SH SH boosted their price objective on shares of ChromaDex from $6.80 to $8.10 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Roth Mkm upped their price target on ChromaDex from $6.00 to $8.00 and gave the stock a "buy" rating in a research note on Wednesday, November 6th.
Get Our Latest Research Report on CDXC
ChromaDex Trading Up 2.3 %
Shares of NASDAQ CDXC traded up $0.18 on Thursday, reaching $7.88. 1,149,439 shares of the company traded hands, compared to its average volume of 871,305. The company has a 50 day moving average of $5.77 and a 200 day moving average of $5.20. ChromaDex has a fifty-two week low of $1.72 and a fifty-two week high of $9.18. The stock has a market capitalization of $612.67 million, a PE ratio of 788.79 and a beta of 2.21.
Insider Activity
In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction dated Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the transaction, the director now owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 9.64% of the company's stock.
Hedge Funds Weigh In On ChromaDex
A number of institutional investors have recently made changes to their positions in CDXC. OneDigital Investment Advisors LLC increased its stake in shares of ChromaDex by 5.5% in the third quarter. OneDigital Investment Advisors LLC now owns 59,414 shares of the company's stock worth $217,000 after buying an additional 3,097 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of ChromaDex by 10.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,172 shares of the company's stock valued at $639,000 after purchasing an additional 17,115 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of ChromaDex by 75.4% during the third quarter. The Manufacturers Life Insurance Company now owns 19,732 shares of the company's stock worth $72,000 after purchasing an additional 8,485 shares during the last quarter. Millrace Asset Group Inc. acquired a new position in ChromaDex in the third quarter worth about $93,000. Finally, FMR LLC bought a new stake in ChromaDex in the third quarter valued at about $55,000. 15.41% of the stock is owned by institutional investors and hedge funds.
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Further Reading
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
